Investing.com - Treace Medical Concepts (NASDAQ: TMCI) reported second quarter EPS of $-0.20, $0.04 better than the analyst estimate of $-0.24. Revenue for the quarter came in at $42M versus the consensus estimate of $40.84M.
Guidance
Treace Medical Concepts sees FY 2023 revenue of $191.00M-$197.00M versus the analyst consensus of $194.00M.
Treace Medical Concepts's stock price closed at $20.13. It is down -19.99% in the last 3 months and up 8.40% in the last 12 months.
Treace Medical Concepts saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Treace Medical Concepts's stock price’s past reactions to earnings here.
According to InvestingPro, Treace Medical Concepts's Financial Health score is "fair performance".
Check out Treace Medical Concepts's recent earnings performance, and Treace Medical Concepts's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar